WHWK
$3.95
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The ...
Recent News
Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027
Whitehawk Therapeutics CEO Dave Lennon outlined the company’s strategy and near-term milestones at the Inaugural Life Sciences Conference in Miami, describing a three-program antibody-drug conjugate (ADC) pipeline built around a shared linker-payload system and focused on targets the company believe
Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
TEM heads into Q4 earnings with expected 82.8% revenue growth, rising oncology momentum and a premium valuation clouding near-term upside.
Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention
TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.
Tempus AI (TEM) Soars 15% on $1.1-Billion Deal
We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]
Hedge funds investors own a significant stake of 37% in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK)
Key Insights Given the large stake in the stock by institutions, Whitehawk Therapeutics' stock price might be...